Table 1.
Patient, tumor, and treatment characteristics
| Parameter | Cohort (n = 70) |
|---|---|
| Patients-no. | 70 |
| Tumors (targets)-no. | 76 |
| Follow-up time-median (range) | 15 (8–22) months |
| Median age-median (range) | 74 (54–91) years |
| Sex | |
| M-no. (%) | 28 (40.0) |
| F-no. (%) | 42 (60.0) |
| Location | |
| Right upper lobe-no. (%) | 18 (23.7) |
| Right middle lobe-no. (%) | 4 (5.3) |
| Right lower lobe-no. (%) | 14 (18.4) |
| Left upper lobe-no. (%) | 14 (18.4) |
| Left lower lobe-no. (%) | 26 (34.2) |
| Central | 28 (36.8) |
| Peripheral | 48 (63.2) |
| Metastatic-no. (%) | 2 (2.9) |
| Lung Primary-no. (%) | 68 (97.1) |
| Histology | |
| Adenocarcinoma | 40 (57.1) |
| Squamous | 17 (24.3) |
| NSCLC-NOS | 11 (15.7) |
| Tumor Size-median (range) | 2.3 (0.6–5.5) cm |
| ≤3 cm | 53 (69.7) |
| >3 cm | 23 (30.3) |
| Median GTV (range) | 6.6 (0.3–150.4) cc |
| Median PTV (range) | 20.8 (12.4–308.2) cc |
| Median total dose (range) | 50 (25–60) Gy |
| 1 fraction (%) | 19 (27.1 %) |
| 3–8 fractions (%) | 51 (72.9 %) |
Abbreviations: NSCLC non-small-cell lung cancer, NOS Not otherwise specified, GTV gross tumor volume, PTV planning target volume